Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products!
Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ICS-H52Ha | Human | Human ICOS / CD278 (C136S, C137S) Protein, His Tag, active dimer (MALS verified) |
![]() ![]() |
![]() ![]() |
|
ICS-R52H9 | Rat | Rat ICOS / CD278 (C137S, C138S) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-M5259 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-M52H8 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-H5258 | Human | Human ICOS / CD278 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ICS-H82E5 | Human | Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Rat ICOS / CD278 (C137S, C138S), His Tag (Cat. No. ICS-R52H9) at 5 μg/mL (100 μL/well) can bind Mouse B7-H2, Fc Tag (Cat. No. B72-M5258) with a linear range of 2-39 ng/mL (QC tested).
The purity of Human ICOS Protein, His Tag (Cat. No. ICS-H52Ha) is more than 90% and the molecular weight of this protein is around 52-62 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Neoplasms | Details | |
MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Mycosis Fungoides | Details | |
Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Alomfilimab | KY-1044 | Phase 2 Clinical | Kymab Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
Feladilimab | GSK-609; GSK-3359609 | Phase 3 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma | Details |
Izuralimab | XmAb-23104; XmAb-104 | Phase 1 Clinical | Xencor Inc | Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms | Details |
Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc, Abbvie Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
This web search service is supported by Google Inc.